{"disease":{"id":"moderate-to-severe-atopic-dermatitis-in-adults","name":"Moderate to severe atopic dermatitis in adults","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f1","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F1","generic_name":"abrocitinib-suspension-f1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":33,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f6","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F6","generic_name":"abrocitinib-suspension-f6","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}